Novel Experimental Drugs for Treatment of Multiple Myeloma

Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging from two to more than 10 years. By using new drugs such as proteasome inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Offidani, Massimo, Corvatta, Laura, Morè, Sonia, Olivieri, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955760/
https://www.ncbi.nlm.nih.gov/pubmed/33727866
http://dx.doi.org/10.2147/JEP.S265288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955760/
https://www.ncbi.nlm.nih.gov/pubmed/33727866
http://dx.doi.org/10.2147/JEP.S265288

Ejemplares similares